Skip to main content

Table 4 Prediction of post modification sites for both N55A and N55B proteins of two genotypes of 1a and 3a

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Genotypes

Phosphorylation

N55A 1a

99 T, 103 S, 106 Y, 117 S, 118 Y, 129 Y, 134 T, 181 S, 201 S, 207 S, 222 S, 225 S, 229 S, 232 S

N55A 3a

99 T, 114 S,118 Y, 129 Y,131 S,146 S,200 T,207 S, 222 S,225 S

N55B 1a

64 Y, 103 Y, 335 S, 346 Y, 347 S, 399 T, 506 S, 513 S, 561 Y

N55B 3a

34 S, 56 S, 106 S, 113 Y, 114 S, 122 S, 142 T, 357 S, 395 T, 409 T

Genotypes

Glycosylation

NS5A 1a

69

NS5A 3a

69,103,105

NS5B 1a

369

NS5B 3a

379, 545

Genotypes

Disulfide bonds

NS5A 1a

39–59, 39–140, 39–142, 39–190, 98 –165

NS5A 3a

39–57, 39–59, 57–140, 101–165, 142–190

NS5B 1a

14–46, 146–170, 243–279, 242–274, 324–366, 521–575

NS5B 3a

9–156, 24–99, 233–253, 252–284, 272–305, 326–376, 504–531

  1. Results showed several phosphorylation and glycosylation sites as well as disulfide bonds in both proteins